Sagimet Biosciences (NASDAQ:SGMT) announced today that it will present updated results from its Phase 2b FASCINATE-2 clinical trial at the Fueling MASH Keystone Symposium, holding from April 12 to 15, 2026, in Vancouver, British Columbia.
The presentation will focus on the metabolic impact of denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor, in patients with metabolic dysfunction-associated steatohepatitis (MASH).
According to the company, histological responders in the denifanstat-treated group showed significant reductions in glycine- and taurine-conjugated bile acids at the 26-week mark.
Bile acid dysregulation is a known driver of liver inflammation and fibrosis in MASH patients.
The observed reductions suggest that denifanstat may offer a multi-pronged therapeutic benefit by not only inhibiting de novo lipogenesis but also potentially modulating the systemic bile acid pool, which is critical for long-term liver health.
The FASCINATE-2 trial remains a cornerstone of Sagimet’s clinical program.
Previous data from the study demonstrated that denifanstat achieved statistically significant improvements in both liver fat reduction and MASH resolution compared to placebo.
The upcoming Vancouver presentation is expected to provide deeper mechanistic insight into how these histological improvements correlate with specific biochemical markers.